Heart Failure
Heart Failure
SC-IN-01648 (February 2025)
Cardiac and Kidney Benefits of Empagliflozin in Heart Failure, Across the Spectrum of Kidney Function: EMPEROR-Reduced Study Subgroup Analysis
SC-IN-01653 (February 2025)
CV and Kidney Outcomes with Empagliflozin in Patients with HFrEF, by Baseline Diabetes Status: EMPEROR-Reduced Prespecified Subgroup Analysis
SC-IN-01652 (February 2025)
Influence of Neprilysin Inhibition on the Efficacy and Safety of Empagliflozin in Patients with HFrEF: EMPEROR-Reduced Prespecified Subgroup Analysis
SC-IN-01651 (February 2025)
Mechanistic Insights of Empagliflozin on Epicardial adipose tissue in Nondiabetic Patients With HFrEF: Findings from EMPA-TROPISM Study
SC-IN-01643 (February 2025)
Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction
SC-IN-01642 (February 2025)
GOLD STANDARD: An infographic dossier on the EMPEROR-Reduced Trial
SC-IN-01655 (February 2025)
Effect of Empagliflozin on Worsening Heart Failure Events in Patients with HFpEF: The EMPEROR-Preserved Trial
SC-IN-01656 (February 2025)
Efficacy of Empagliflozin in Patients with true HFpEF and HFmrEF: EMPEROR-Preserved Trial
SC-IN-01647 (February 2025)
Interplay of MRAs and Empagliflozin in Heart Failure- EMPEROR-Reduced Study: Subgroup Analysis by Baseline MRA Use
SC-IN-01650 (February 2025)